Trial Profile
A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs IMU 131 (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HERIZON
- Sponsors Imugene
- 11 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Aug 2024.
- 11 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2024.
- 24 Oct 2023 Results assessing antibody and clinical responses in patients with advanced or metastatic Her2-overexpressing GC naive to Her2 therapy presented at the 48th European Society for Medical Oncology Congress